BACKGROUND: The capacity of CD8(+) T cells to control infections and mediate antitumor immunity requires the development and survival of effector and memory cells. IL-21 has emerged as a potent inducer of CD8(+) T-cell effector function and memory development in mouse models of infectious disease. However, the role of IL-21 and associated signaling pathways in protective CD8(+) T-cell immunity in human subjects is unknown. OBJECTIVE: We sought to determine which signaling pathways mediate the effects of IL-21 on human CD8(+) T cells and whether defects in these pathways contribute to disease pathogenesis in patients with primary immunodeficiencies caused by mutations in components of the IL-21 signaling cascade. METHODS: Human primary immunodeficiencies resulting from monogenic mutations provide a unique opportunity to assess the requirement for particular molecules in regulating human lymphocyte function. Lymphocytes from patients with loss-of-function mutations in signal transducer and activator of transcription 1 (STAT1), STAT3, or IL-21 receptor (IL21R) were used to assess the respective roles of these genes in human CD8(+) T-cell differentiation in vivo and in vitro. RESULTS: Mutations in STAT3 and IL21R, but not STAT1, led to a decrease in multiple memory CD8(+) T-cell subsets in vivo, indicating that STAT3 signaling, possibly downstream of IL-21R, regulates the memory cell pool. Furthermore, STAT3 was important for inducing the lytic machinery in IL-21-stimulated naive CD8(+) T cells. However, this defect was overcome by T-cell receptor engagement. CONCLUSION: The IL-21R/STAT3 pathway is required for many aspects of human CD8(+) T-cell behavior but in some cases can be compensated by other signals. This helps explain the relatively mild susceptibility to viral disease observed in STAT3- and IL-21R-deficient subjects. Published by Mosby, Inc.
BACKGROUND: The capacity of CD8(+) T cells to control infections and mediate antitumor immunity requires the development and survival of effector and memory cells. IL-21 has emerged as a potent inducer of CD8(+) T-cell effector function and memory development in mouse models of infectious disease. However, the role of IL-21 and associated signaling pathways in protective CD8(+) T-cell immunity in human subjects is unknown. OBJECTIVE: We sought to determine which signaling pathways mediate the effects of IL-21 on human CD8(+) T cells and whether defects in these pathways contribute to disease pathogenesis in patients with primary immunodeficiencies caused by mutations in components of the IL-21 signaling cascade. METHODS: Human primary immunodeficiencies resulting from monogenic mutations provide a unique opportunity to assess the requirement for particular molecules in regulating human lymphocyte function. Lymphocytes from patients with loss-of-function mutations in signal transducer and activator of transcription 1 (STAT1), STAT3, or IL-21 receptor (IL21R) were used to assess the respective roles of these genes in human CD8(+) T-cell differentiation in vivo and in vitro. RESULTS: Mutations in STAT3 and IL21R, but not STAT1, led to a decrease in multiple memory CD8(+) T-cell subsets in vivo, indicating that STAT3 signaling, possibly downstream of IL-21R, regulates the memory cell pool. Furthermore, STAT3 was important for inducing the lytic machinery in IL-21-stimulated naive CD8(+) T cells. However, this defect was overcome by T-cell receptor engagement. CONCLUSION: The IL-21R/STAT3 pathway is required for many aspects of human CD8(+) T-cell behavior but in some cases can be compensated by other signals. This helps explain the relatively mild susceptibility to viral disease observed in STAT3- and IL-21R-deficient subjects. Published by Mosby, Inc.
Entities:
Keywords:
AD-HIES; Autosomal dominant hyper-IgE syndrome; B-cell lymphoma; BCL; CTV; CellTrace Violet; Central memory T; EOMES; Effector memory T; Effector memory T cells expressing CD45RA; Eomesodermin; IL-21; IL-21 receptor; IL-21R; LCMV; Lymphocytic choriomeningitis virus; PB; PID; Peripheral blood; Primary immunodeficiency; STAT; STAT1; STAT3; Signal transducer and activator of transcription; T(CM); T(EM); T(EMRA); T-cell receptor; TCR; differentiation; human CD8(+) T cells; memory
Authors: Andrew M Intlekofer; Naofumi Takemoto; E John Wherry; Sarah A Longworth; John T Northrup; Vikram R Palanivel; Alan C Mullen; Christopher R Gasink; Susan M Kaech; Joseph D Miller; Laurent Gapin; Kenneth Ryan; Andreas P Russ; Tullia Lindsten; Jordan S Orange; Ananda W Goldrath; Rafi Ahmed; Steven L Reiner Journal: Nat Immunol Date: 2005-11-06 Impact factor: 25.606
Authors: Hak-Ling Ma; Matthew J Whitters; Richard F Konz; Mayra Senices; Deborah A Young; Michael J Grusby; Mary Collins; Kyriaki Dunussi-Joannopoulos Journal: J Immunol Date: 2003-07-15 Impact factor: 5.422
Authors: Rong Zeng; Rosanne Spolski; Steven E Finkelstein; SangKon Oh; Panu E Kovanen; Christian S Hinrichs; Cynthia A Pise-Masison; Michael F Radonovich; John N Brady; Nicholas P Restifo; Jay A Berzofsky; Warren J Leonard Journal: J Exp Med Date: 2005-01-03 Impact factor: 14.307
Authors: Daniel Kotlarz; Natalia Ziętara; Gulbu Uzel; Thomas Weidemann; Christian J Braun; Jana Diestelhorst; Peter M Krawitz; Peter N Robinson; Jochen Hecht; Jacek Puchałka; E Michael Gertz; Alejandro A Schäffer; Monica G Lawrence; Lela Kardava; Dietmar Pfeifer; Ulrich Baumann; Eva-Doreen Pfister; Eric P Hanson; Axel Schambach; Roland Jacobs; Hans Kreipe; Susan Moir; Joshua D Milner; Petra Schwille; Stefan Mundlos; Christoph Klein Journal: J Exp Med Date: 2013-02-25 Impact factor: 14.307
Authors: Junmei Wang; Farah Hasan; Amanda C Frey; Haiyan S Li; Jungsun Park; Ke Pan; Cara Haymaker; Chantale Bernatchez; Dean A Lee; Stephanie S Watowich; Cassian Yee Journal: Cancer Immunol Res Date: 2020-03-25 Impact factor: 11.151